about
Epigenetic mechanisms underlying the link between non-alcoholic fatty liver diseases and nutritionMiR-155 has a protective role in the development of non-alcoholic hepatosteatosis in mice.Circulating hepatitis B surface antigen particles carry hepatocellular microRNAs.Independent effects of sham laparotomy and anesthesia on hepatic microRNA expression in rats.Elevated miR-33a and miR-224 in steatotic chronic hepatitis C liver biopsiesmiR-122 negatively correlates with liver fibrosis as detected by histology and FibroScan.Effect of miR-34a in regulating steatosis by targeting PPARα expression in nonalcoholic fatty liver disease.MiR-9a-5p regulates proliferation and migration of hepatic stellate cells under pressure through inhibition of Sirt1.Epigenetic regulation of miR-34a expression in alcoholic liver injury.Isocaloric Pair-Fed High-Carbohydrate Diet Induced More Hepatic Steatosis and Inflammation than High-Fat Diet Mediated by miR-34a/SIRT1 Axis in Mice.Genetic and epigenetic variants influencing the development of nonalcoholic fatty liver disease.Impact of maternal undernutrition around the time of conception on factors regulating hepatic lipid metabolism and microRNAs in singleton and twin fetusesZebrafish models of human liver development and diseasemiR-382 targeting PTEN-Akt axis promotes liver regenerationInhibition of Dexamethasone-induced Fatty Liver Development by Reducing miR-17-5p Levels.Processing of miR17-92 Cluster in Hepatic Stellate Cells Promotes Hepatic Fibrogenesis During Alcohol-Induced Injury.MicroRNAs in Liver Disease: Bench to Bedside.Identification of miR-31-5p, miR-141-3p, miR-200c-3p, and GLT1 as human liver aging markers sensitive to donor-recipient age-mismatch in transplants.MicroRNA silencing and the development of novel therapies for liver disease.miRNAs, polyphenols, and chronic disease.Circulating miRNA profiling to identify biomarkers of dysmetabolism.Dual role of microRNAs in NAFLD.MicroRNAs: the fine modulators of liver development and function.Progress in the search for circulating biomarkers of nonalcoholic fatty liver disease.MicroRNA-19b Expression in Human Biliary Atresia Specimens and Its Role in BA-Related Fibrosis.miRNA-1 targets fibronectin1 and suppresses the migration and invasion of the HEp2 laryngeal squamous carcinoma cell line.Inhibitory effects of microRNA 19b in hepatic stellate cell-mediated fibrogenesis.Serum microRNAs; miR-30c-5p, miR-223-3p, miR-302c-3p and miR-17-5p could be used as novel non-invasive biomarkers for HCV-positive cirrhosis and hepatocellular carcinoma.An annual topic highlight: alcohol and liver, 2011.MicroRNA-155 Deficiency Leads to Decreased Atherosclerosis, Increased White Adipose Tissue Obesity, and Non-alcoholic Fatty Liver Disease: A NOVEL MOUSE MODEL OF OBESITY PARADOX.MiRNA-17 encoded by the miR-17-92 cluster increases the potential for steatosis in hepatoma cells by targeting CYP7A1.The Emerging Role of MicroRNAs in Hepatocellular CarcinomaUrsodeoxycholic acid improves liver function via phenylalanine/tyrosine pathway and microbiome remodelling in patients with liver dysfunction
P2860
Q26822513-3442E35B-211F-4CBE-9BAE-AA8620D7DABEQ31132757-8F338967-3E99-4013-A8F4-2B55C661D8C3Q34217300-F3EE2F66-92DD-4AB3-946D-0E69B71982F9Q34346360-5096A443-843A-4246-A031-1517750AFA2CQ34467266-76D29976-5B8A-4871-B621-D208B7187E1AQ35819563-C48CD70D-F5E2-497D-A500-BBB7B5C047BCQ36018329-F657E7B0-3CCF-4B8A-87BD-D037CCD55436Q36050488-B4474738-835B-4E8F-831E-059307DEFD0EQ36204201-1D93904F-DF7A-45F1-8147-623DCE1DD740Q36320944-E0DFEA92-834A-4AF2-9696-32EF3EBC862BQ36450465-69C3564E-669E-48B0-8A8D-794360326FEEQ36480300-227E8C3D-A511-415E-988B-DA4E90946402Q36669372-FBE9465B-6825-4FA6-A0C4-C5EFAF25D915Q36738912-B0858201-5128-424A-97F8-371956D20D6CQ36756799-CE62A3C9-3C28-44DF-B989-00C091C2755BQ37059261-E1F51D17-B930-4CBA-A645-520956889257Q37613598-078381E4-5647-4296-9A63-C6F7A48F433BQ37678208-D8D576BB-BF3E-4743-880F-B8FF6D8CACF5Q38002726-9881923A-6D9D-4A2A-98F7-D693F9CA987BQ38061096-ED82286E-2DD1-4781-B072-6743ADE99D2AQ38066239-AB348624-9964-4AC4-9003-85B407B9AB4DQ38099737-640C4759-418A-422C-9765-F788C29695F1Q38187190-3EDF4EEB-1B8D-4DE5-9DBA-1F1871A2A691Q38246145-A6C16574-98DA-49A4-B01E-18F093F77289Q39022918-60EEE285-1B0A-498D-A3B1-AC493F7C22CAQ39472687-974F141E-8311-4415-9E3F-FB4AD9293264Q42144833-BF681D80-168B-4D92-8A53-F3ECC491D3D9Q42181602-BCFF548C-C338-4E5D-BB48-DBC74B7738A1Q42740872-53EFEA86-7436-43E7-89CA-C577EE0677B8Q51276219-E2F706BB-FC86-4F9B-B12C-C190D42797B0Q54985271-E55EAD7A-D74F-4D49-B385-5DF246A27705Q57001209-BB8BC258-C815-4C43-9D6C-020BCECB5955Q58796002-319B6075-5D91-44B9-B06B-39CA7BFD2159
P2860
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on May 2011
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
microRNAs: fad or future of liver disease.
@en
microRNAs: fad or future of liver disease.
@nl
type
label
microRNAs: fad or future of liver disease.
@en
microRNAs: fad or future of liver disease.
@nl
prefLabel
microRNAs: fad or future of liver disease.
@en
microRNAs: fad or future of liver disease.
@nl
P2093
P2860
P356
P1476
microRNAs: fad or future of liver disease.
@en
P2093
Ashley M Lakner
Herbert L Bonkovsky
Laura W Schrum
P2860
P304
P356
10.3748/WJG.V17.I20.2536
P407
P577
2011-05-01T00:00:00Z